Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced that the FDA has cleared its Elecsys Phospho-Tau (217P) Plasma (pTau217) blood test that identifies amyloid pathology associated with Alzheimer’s disease. The test is cleared for people 55 and older with signs of cognitive decline to be used in conjunction with clinical information in assessing Alzheimer’s risk. When the FDA approved the first […]
Alzheimer's
Medtech stories we missed this week: March 3, 2017
Several clinical study results were published this week, while other companies reached distribution deals. Here are some medtech stories we missed this week but were still worth mentioning. 1. Health Canada approves Ventripoint’s complete heart analysis system for 2D ultrasounds Ventripoint Diagnostics received a license from Health Canada for its new VMS-Plus machine and the 4-chamber (4C) heart […]
